

## Press Release

### Profit Before Tax up 25% to Rs. 168 Crores for the Quarter

**Vadodara, November 7<sup>th</sup>, 2024**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter ended 30<sup>th</sup> September, 2024.

#### Financial Highlights

- Net Sales increased by 3% to Rs.1648 Crores.
- EBITDA up 18% to Rs. 257 Crores
- EBITDA Margin at 15.6% of Sales
- Net Profit up 12% to Rs.153 Crores.

**Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said** "India's Branded Business continues to enhance execution capabilities in both quality and scale, with the Specialty and Animal Health segments showing good growth. The USFDA successfully inspected our Oncology Formulation Facility (F-2) without any form 483 observations."

#### Operational Highlights

##### India Branded Business

- India Branded Business grew 6% to Rs. 609 Crores for the quarter.
- Recorded good growths in specialty therapies like 8% in Gynaecology, 11% in Cardiology, 18% in Anti Diabetic and 13% in Ophthalmology therapies.
- Animal Health business grew 20% for the quarter with basket of strong brands driving outperformance.
- 3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.

##### International Business

- US Generics grew 5% to Rs. 467 Crores for the quarter.
- 8 Launches in the US market during the quarter.
- Ex-US International Formulations grew 18% to Rs. 298 Crores for the quarter.
- 9 ANDA approvals received during the quarter, 214 Cumulative ANDA approvals.

### **ALEMBIC PHARMACEUTICALS LIMITED**

## API Business

- API business at Rs. 274 Crores for the quarter.

The summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q2 FY25	Q2 FY24	% Change	H-1 FY25	H-1 FY24	% Change
<b>Formulation</b>						
India	609	577	6%	1181	1101	7%
USA	467	444	5%	928	834	11%
Ex- US	298	252	18%	568	518	10%
<b>API</b>	274	322	(15%)	532	628	(15%)
<b>Total</b>	<b>1648</b>	<b>1595</b>	<b>3%</b>	<b>3210</b>	<b>3081</b>	<b>4%</b>

### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5200 are well recognized by doctors and patients.

Information about the company can be found at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com);  
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information, contact:**

**Ajay Kumar Desai**

**Phone: +91 022- 66953681**

**Email: [ajay.desai@alembic.co.in](mailto:ajay.desai@alembic.co.in)**

## **ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123